BerGenBio AS of Norway has announced the appointment of Barrie Ward, the chairman of CellCentric Ltd, to its board of directors. Dr Ward has had a long career in both academia and industry including leading GlaxoSmithKline Plc’s microbiology division for 10 years to 1994. He was also chief executive of KuDOS Pharmaceuticals Ltd until its sale to AstraZeneca Plc in 2006. Dr Ward is currently also a board member of Spirogen Ltd, Pharming NV and Cancer Research Technology Ltd.
BerGenBio announced the appointment on 14 August 2012.
Copyright 2012 Evernow Publishing Ltd